SG10201811729PA - Membrane-penetrating peptides to enhance transfection and compositions and methods for using same - Google Patents

Membrane-penetrating peptides to enhance transfection and compositions and methods for using same

Info

Publication number
SG10201811729PA
SG10201811729PA SG10201811729PA SG10201811729PA SG10201811729PA SG 10201811729P A SG10201811729P A SG 10201811729PA SG 10201811729P A SG10201811729P A SG 10201811729PA SG 10201811729P A SG10201811729P A SG 10201811729PA SG 10201811729P A SG10201811729P A SG 10201811729PA
Authority
SG
Singapore
Prior art keywords
cargo
membrane
compositions
methods
peptides
Prior art date
Application number
SG10201811729PA
Inventor
Mollerat Du Jeu Xavier De
Original Assignee
Life Technologies Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Life Technologies Corp filed Critical Life Technologies Corp
Publication of SG10201811729PA publication Critical patent/SG10201811729PA/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/001—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof by chemical synthesis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/54—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
    • A61K47/543—Lipids, e.g. triglycerides; Polyamines, e.g. spermine or spermidine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/54—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
    • A61K47/543—Lipids, e.g. triglycerides; Polyamines, e.g. spermine or spermidine
    • A61K47/544—Phospholipids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
    • A61K47/64—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent
    • A61K47/645—Polycationic or polyanionic oligopeptides, polypeptides or polyamino acids, e.g. polylysine, polyarginine, polyglutamic acid or peptide TAT
    • A61K47/6455—Polycationic oligopeptides, polypeptides or polyamino acids, e.g. for complexing nucleic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/87—Introduction of foreign genetic material using processes not otherwise provided for, e.g. co-transformation
    • C12N15/88—Introduction of foreign genetic material using processes not otherwise provided for, e.g. co-transformation using microencapsulation, e.g. using amphiphile liposome vesicle
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
    • C07K2319/02—Fusion polypeptide containing a localisation/targetting motif containing a signal sequence
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2810/00—Vectors comprising a targeting moiety
    • C12N2810/40—Vectors comprising a peptide as targeting moiety, e.g. a synthetic peptide, from undefined source

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Genetics & Genomics (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Biophysics (AREA)
  • Organic Chemistry (AREA)
  • Epidemiology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Biochemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biotechnology (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Biomedical Technology (AREA)
  • General Engineering & Computer Science (AREA)
  • Physics & Mathematics (AREA)
  • Plant Pathology (AREA)
  • Microbiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Peptides Or Proteins (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)

Abstract

MEMBRANE-PENETRATING PEPTIDES TO ENHANCE TRANSFECTION AND COMPOSITIONS AND METHODS FOR USING SAME The present invention is directed to non-naturally occurring peptides containing a membrane-penetrating amino acid sequence and further at least one polycationic moiety or peptide sequence. The peptides are suitable for use in delivery a cargo to the interior of a cell. Suit - able cargo includes nucleic acid molecules (including DNA, RNA or PNA), polypeptides, or other biologically active molecules. The present invention is further directed to transfection complexes containing the non-naturally occurring peptides of the present invention in non-covalent association with at least one cationic lipid and a cargo to be delivered to the interior of a cell. The invention further relates to methods for the preparation and use of the non-naturally occurring peptides for the formation of transfection complexes and the delivery of a cargo to the interior of a cell in culture, an animal or a human. The invention also relates to compositions and kits useful for transfecting cells. [Fig. 9B]
SG10201811729PA 2013-12-12 2014-12-12 Membrane-penetrating peptides to enhance transfection and compositions and methods for using same SG10201811729PA (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US201361915429P 2013-12-12 2013-12-12

Publications (1)

Publication Number Publication Date
SG10201811729PA true SG10201811729PA (en) 2019-02-27

Family

ID=52273587

Family Applications (2)

Application Number Title Priority Date Filing Date
SG10201811729PA SG10201811729PA (en) 2013-12-12 2014-12-12 Membrane-penetrating peptides to enhance transfection and compositions and methods for using same
SG11201604697TA SG11201604697TA (en) 2013-12-12 2014-12-12 Membrane-penetrating peptides to enhance transfection and compositions and methods for using same

Family Applications After (1)

Application Number Title Priority Date Filing Date
SG11201604697TA SG11201604697TA (en) 2013-12-12 2014-12-12 Membrane-penetrating peptides to enhance transfection and compositions and methods for using same

Country Status (11)

Country Link
US (3) US9856496B2 (en)
EP (2) EP3756690A3 (en)
JP (2) JP6912887B2 (en)
KR (1) KR102532559B1 (en)
CN (2) CN106456793B (en)
AU (2) AU2014361806B2 (en)
BR (1) BR112016013516A8 (en)
CA (1) CA2933561A1 (en)
ES (1) ES2808866T3 (en)
SG (2) SG10201811729PA (en)
WO (1) WO2015089487A1 (en)

Families Citing this family (28)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2872476C (en) * 2012-05-02 2020-07-07 Life Technologies Corporation High yield transient expression in mammalian cells using unique pairing of high density growth and transfection medium and expression enhancers
WO2013188705A2 (en) 2012-06-15 2013-12-19 Soft Machines, Inc. A virtual load store queue having a dynamic dispatch window with a unified structure
EP2862069A4 (en) 2012-06-15 2016-12-28 Soft Machines Inc An instruction definition to implement load store reordering and optimization
EP2862087A4 (en) 2012-06-15 2016-12-14 Soft Machines Inc A disambiguation-free out of order load store queue
WO2013188306A1 (en) 2012-06-15 2013-12-19 Soft Machines, Inc. Reordered speculative instruction sequences with a disambiguation-free out of order load store queue
EP2862084A4 (en) 2012-06-15 2016-11-30 Soft Machines Inc A method and system for implementing recovery from speculative forwarding miss-predictions/errors resulting from load store reordering and optimization
CN104583943B (en) 2012-06-15 2018-06-08 英特尔公司 Possess the virtual load storage queue of the dynamic assignment window with distributed frame
BR112016013516A8 (en) 2013-12-12 2020-05-19 Life Technologies Corp transfection complex and its use to increase charge molecule transport in cells and for the treatment of cancer and gene therapy, as well as an in vitro method for delivering a polyanion to a cell
JP7199809B2 (en) 2015-02-13 2023-01-06 ファクター バイオサイエンス インコーポレイテッド Nucleic acid product and its administration method
WO2017011598A1 (en) 2015-07-13 2017-01-19 Life Technologies Corporation System and method for improved transient protein expression in cho cells
WO2018035377A1 (en) 2016-08-17 2018-02-22 Factor Bioscience Inc. Nucleic acid products and methods of administration thereof
KR102581578B1 (en) * 2016-09-30 2023-09-25 라이프 테크놀로지스 코포레이션 Serum-free suspension system for lentivirus production
US11782050B2 (en) 2017-09-19 2023-10-10 Cannametrix, Llc Cell-based assay for quantifying the potency and efficacy of cannabinoids and/or terpenoids, and methods of use thereof
GB201821269D0 (en) 2018-12-28 2019-02-13 Nippon Shinyaku Co Ltd Myostatin signal inhibitor
US11608491B2 (en) 2019-02-22 2023-03-21 Life Technologies Corporation Suspension system for adeno associated virus production
US20220160888A1 (en) * 2019-04-01 2022-05-26 Industry-University Cooperation Foundation Hanyang University Cp2c-targeting peptide-based anticancer agent
KR102261371B1 (en) * 2019-04-01 2021-06-08 한양대학교 산학협력단 Anticancer peptide for targeting CP2c
US20220325299A1 (en) * 2019-08-05 2022-10-13 Polyplus Transfection Compositions for transfecting a nucleic acid molecule into a cell comprising benzo-fused heterocyclic compounds grafted to a cationic polymer, and their applications
KR102515464B1 (en) * 2020-04-29 2023-03-28 연세대학교 원주산학협력단 Cytotoxic mitigating membrane permeable peptides for improving nucleic acid or genetransfection efficiency and use thereof
EP4368186A1 (en) 2021-07-08 2024-05-15 Nippon Shinyaku Co., Ltd. Nephrotoxicity reducing agent
IL310001A (en) 2021-07-08 2024-03-01 Nippon Shinyaku Co Ltd Precipitation suppressing agent
WO2023282344A1 (en) 2021-07-08 2023-01-12 日本新薬株式会社 Nephrotoxicity reducing agent
CN113563429A (en) * 2021-07-19 2021-10-29 天津大学 Nucleic acid delivery system based on alkylated polypeptide, preparation method and application
WO2023014909A1 (en) * 2021-08-04 2023-02-09 AJK Biopharmaceutical, LLC Amphiphilic peptides for nucleic acid and protein delivery
CN114106095B (en) * 2021-11-11 2023-06-09 华南理工大学 Cell autophagy detection molecular probe based on aggregation-induced emission principle, and preparation method and application thereof
WO2024006937A1 (en) 2022-06-30 2024-01-04 Life Technologies Corporation Lipid compositions for in vivo delivery
GB202211597D0 (en) 2022-08-09 2022-09-21 Nchain Licensing Ag Computer-implemented method and system
CN115947817A (en) * 2023-02-22 2023-04-11 广州庆毅生物医药科技有限公司 Tumor-related polypeptide and preparation method and application thereof

Family Cites Families (40)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4897355A (en) 1985-01-07 1990-01-30 Syntex (U.S.A.) Inc. N[ω,(ω-1)-dialkyloxy]- and N-[ω,(ω-1)-dialkenyloxy]-alk-1-yl-N,N,N-tetrasubstituted ammonium lipids and uses therefor
FR2645866B1 (en) 1989-04-17 1991-07-05 Centre Nat Rech Scient NEW LIPOPOLYAMINES, THEIR PREPARATION AND THEIR USE
US5279833A (en) 1990-04-04 1994-01-18 Yale University Liposomal transfection of nucleic acids into animal cells
US5334761A (en) 1992-08-28 1994-08-02 Life Technologies, Inc. Cationic lipids
US5316948A (en) 1992-09-04 1994-05-31 Life Technologies, Inc. N4 -methyl-2'-deoxycytidine 5'-triphosphate and its use in polymerase-catalyzed nucleic acid syntheses
WO1995002698A1 (en) 1993-07-12 1995-01-26 Life Technologies, Inc. Composition and methods for transfecting eukaryotic cells
US5674908A (en) 1993-12-20 1997-10-07 Life Technologies, Inc. Highly packed polycationic ammonium, sulfonium and phosphonium lipids
US6075012A (en) 1994-02-11 2000-06-13 Life Technologies, Inc. Reagents for intracellular delivery of macromolecules
US5627159A (en) 1994-10-27 1997-05-06 Life Technologies, Inc. Enhancement of lipid cationic transfections in the presence of serum
US6051429A (en) 1995-06-07 2000-04-18 Life Technologies, Inc. Peptide-enhanced cationic lipid transfections
US5736392A (en) 1995-06-07 1998-04-07 Life Technologies, Inc. Peptide-enhanced cationic lipid transfections
US5744335A (en) 1995-09-19 1998-04-28 Mirus Corporation Process of transfecting a cell with a polynucleotide mixed with an amphipathic compound and a DNA-binding protein
SE9804614A0 (en) 1998-07-06 2000-01-07 A+ Science Invest Ab New peptides and use thereof
ES2296419T3 (en) 1998-11-12 2008-04-16 Invitrogen Corporation TRANSFECTION REAGENTS.
US6664040B2 (en) 2000-05-23 2003-12-16 The Regents Of The University Of California Compositions and methods for delivery of a molecule into a cell
JP5610659B2 (en) * 2000-07-21 2014-10-22 ルバンス セラピュティックス インク．Ｒｅｖａｎｃｅ Ｔｈｅｒａｐｅｕｔｉｃｓ，Ｉｎｃ． Multi-component biological transport system
GB0103110D0 (en) 2000-08-25 2001-03-28 Aventis Pharma Inc A membrane penetrating peptide encoded by a nuclear localization sequence from human period 1
GB0106315D0 (en) * 2001-03-14 2001-05-02 Ich Productions Ltd Transfection complexes
CA2513072A1 (en) 2003-01-09 2004-07-29 Invitrogen Corporation Cellular delivery and activation polypeptide-nucleic acid complexes
JP4846588B2 (en) 2003-05-22 2011-12-28 モレキュラー、トランスファー、インコーポレイテッド Novel lipids for nucleic acid transfection
BRPI0413521A (en) * 2003-08-14 2006-10-10 Diatos amino acid sequences that facilitate the penetration of a substance of interest into cells and / or cell nuclei
US20050288246A1 (en) * 2004-05-24 2005-12-29 Iversen Patrick L Peptide conjugated, inosine-substituted antisense oligomer compound and method
WO2007069068A2 (en) * 2005-12-16 2007-06-21 Diatos Cell penetrating peptide conjugates for delivering nucleic acids into cells
CA2646833C (en) 2005-12-30 2019-07-30 Evonik Roehm Gmbh Peptides useful as cell-penetrating peptides
WO2007113687A2 (en) 2006-03-30 2007-10-11 Diatos S.A. Camptothecin-cell penetrating peptide conjugates and pharmaceutical compositions containing the same
EP2604255B1 (en) 2006-05-05 2017-10-25 Molecular Transfer, Inc. Novel reagents for transfection of eukaryotic cells
EP2130837B1 (en) 2007-03-07 2013-11-27 National Center for Global Health and Medicine Novel nuclear translocation peptide
WO2010075575A1 (en) 2008-12-23 2010-07-01 Biopips, Inc. Compositions and methods for re-programming cells without genetic modification
US20110053829A1 (en) * 2009-09-03 2011-03-03 Curevac Gmbh Disulfide-linked polyethyleneglycol/peptide conjugates for the transfection of nucleic acids
WO2011127210A1 (en) 2010-04-06 2011-10-13 Massachusetts Institute Of Technology Targeted delivery of nucleic acids
CA2800741C (en) * 2010-05-30 2018-07-24 The Governing Council Of The University Of Toronto Mitochondrial penetrating peptides as carriers for anticancer compounds
KR101590674B1 (en) 2010-06-14 2016-02-02 에프. 호프만-라 로슈 아게 Cell-penetrating peptides and uses therof
WO2012000104A1 (en) 2010-06-30 2012-01-05 Protiva Biotherapeutics, Inc. Non-liposomal systems for nucleic acid delivery
EP2640700B1 (en) 2010-11-15 2018-10-31 Life Technologies Corporation Amine-containing transfection reagents and methods for making and using same
CN102153629B (en) * 2011-01-20 2013-07-24 华中科技大学 Short peptide and application thereof
US8853145B2 (en) * 2011-11-14 2014-10-07 Carlos Witte-Hoffmann BLID; a novel protein domain for interaction with the Bcl-2 family of proteins
CA2867188A1 (en) * 2012-03-15 2013-09-19 Permeon Biologics, Inc. Cell penetrating compositions for delivery of intracellular antibodies and antibody-like moieties and methods of use
BR112016013516A8 (en) 2013-12-12 2020-05-19 Life Technologies Corp transfection complex and its use to increase charge molecule transport in cells and for the treatment of cancer and gene therapy, as well as an in vitro method for delivering a polyanion to a cell
KR102476764B1 (en) * 2015-12-23 2022-12-14 에스케이하이닉스 주식회사 Isolation structure and method for manufacturing the same
US9926825B2 (en) 2016-04-19 2018-03-27 GM Global Technology Operations LLC Method and apparatus for exhaust purification for an internal combustion engine

Also Published As

Publication number Publication date
EP3756690A2 (en) 2020-12-30
BR112016013516A2 (en) 2017-08-08
CA2933561A1 (en) 2015-06-18
AU2020202002A1 (en) 2020-04-09
AU2014361806B2 (en) 2019-12-19
KR20160103024A (en) 2016-08-31
US10760098B2 (en) 2020-09-01
KR102532559B1 (en) 2023-05-16
JP2017500856A (en) 2017-01-12
JP6985347B2 (en) 2021-12-22
US20180163231A1 (en) 2018-06-14
US20200392537A1 (en) 2020-12-17
AU2014361806A1 (en) 2016-07-28
ES2808866T3 (en) 2021-03-02
US20150211021A1 (en) 2015-07-30
EP3079723A1 (en) 2016-10-19
US9856496B2 (en) 2018-01-02
SG11201604697TA (en) 2016-07-28
JP6912887B2 (en) 2021-08-04
WO2015089487A1 (en) 2015-06-18
CN113105559A (en) 2021-07-13
BR112016013516A8 (en) 2020-05-19
EP3756690A3 (en) 2021-03-17
JP2020015747A (en) 2020-01-30
EP3079723B1 (en) 2020-05-27
AU2020202002B2 (en) 2021-08-05
CN106456793B (en) 2021-04-30
CN106456793A (en) 2017-02-22

Similar Documents

Publication Publication Date Title
SG10201811729PA (en) Membrane-penetrating peptides to enhance transfection and compositions and methods for using same
Zuris et al. Cationic lipid-mediated delivery of proteins enables efficient protein-based genome editing in vitro and in vivo
MX2020006065A (en) Methods and products for nucleic acid production and delivery.
EA201790968A1 (en) PEPTID-MEDIATED DELIVERY OF THE DIRECTED RNA ENDONUCLEASE IN CELLS
WO2010129023A3 (en) Supercharged proteins for cell penetration
WO2008147816A3 (en) Compositions and methods for the display of proteins on the surface of bacteria and their derived vesicles and uses thereof
BR112013024220B8 (en) METHODS OF INTRODUCTION OF A NUCLEIC ACID OF INTEREST IN A CELL-WALLED PLANT CELL, OF STABLE EXPRESSION OF A GENE AND OF TRANSFER OF A GENE TO A PLANT CELL
RU2020113032A (en) NEW PEPTIDES AND PEPTID COMBINATIONS FOR USE IN LUNG CANCER IMMUNOTHERAPY, INCLUDING NON-SMALL CELL LUNG CANCER (NSCLC) AND OTHER CANCER SPECIES
BRPI0816405B8 (en) RNA and cationic peptide complexes for transfection and immunostimulation
Zuris et al. Efficient delivery of genome-editing proteins in vitro and in vivo
MX2013003681A (en) Engineered nucleic acids and methods of use thereof.
WO2007130073A3 (en) Novel reagents for transfection of eukaryotic cells
IL192131A0 (en) Peptides useful as cell-penetrating peptides
WO2012135805A3 (en) Delivery and formulation of engineered nucleic acids
EP2583976A3 (en) Peptide vaccines with SEQ ID NO: 210, 196, 202, 213, 214, 214 or 223 for cancers expressing tumor-associated antigens
AU2012300633A8 (en) Cell- penetrating peptides having a central hydrophobic domain
MX2010005451A (en) System for delivery into a xcr1 positive cell and uses thereof.
RU2014110901A (en) PEPTIDE PARTICLES AND THEIR APPLICATION
IN2014CN04734A (en)
RU2013116447A (en) SYSTEMS AND METHODS OF DELIVERY OF BIOACTIVE PRODUCTS USING VEHICLE SEQUENCES ORIGINING FROM BACTERIAL TOXIN
WO2014070687A3 (en) Polycationic methyl phospholipids for improved delivery of nucleic acids to eukaryotic cells
WO2013134129A3 (en) Derivatized polyglucosamines for delivery of small molecules, peptides, and proteins
MY180183A (en) Methods and compositions for preventing norleucine misincorporation into proteins
WO2023018990A3 (en) Lipids for nucleic acid delivery
WO2015120542A8 (en) Hybrid proteins and uses thereof